Replies to post #279727 on Amarin Corp Plc (AMRN)

[HDGabor]

JL-

Actually the rule in most cases is the cheapest alternative is awarded the Tier one and in most cases that is the generic..

Do you consider that a lot of plan tiering as:
1: preferred generics
2: non-preferred generics
3: preferred brand
2: non-preferred brand

Its just it will not be Amarin vs Lovaza it will be Teva {if they make gen Lovaza} against Reddi and Hikma..

a.) several companies produce gen Lovaza ... inc. TEVA
(b) TEVA will produce gen Vascepa also ... it will be Teva against Reddi and Hikma and TEVA ...

The same thing will happen to the generics unless they can sell gen Vascepa cheaper than gen Lovaza..(not likely)

How about the pricing of gen Lovaza by TEVA against gen Vascepa by TEVA ... ?

Best,
G

[sts66]

Cannot believe that as often as this has been discussed here, and confirmed by actual pharmacists, that you still don't get it - GL will NOT be a substitute for GV! A doc writes a scrip for V, at pharmacy they check "is there a GV available?" - answer if AMRN loses appeal will be YES, patient will be given GV unless they want to pay for brand V out of pocket. This has nothing to do with formulary tiers.